Summary
Ten patients with disseminated adenocarcinoma were treated with combination chemotherapy employing Adriamycin and Baker's Antifolate (BAF). There were seven patients with lung adenocarcinoma, two of whom achieved partial remission while the remaining five had their disease stabilized. Drug toxicity to the bone marrow, gastrointestinal mucosa, and skin was dose-limiting and was greater than the known toxicities of the individual drugs. Pharmacological studies of both drugs were performed on five patients to determine whether abnormal pharmacokinetics could explain this collateral toxicity. Adriamycin plasma concentrations and disappearance seemed to be unaffected by BAF. However, BAF levels were prolonged, apparently due to an Adriamycin effect on the plasma elimination of BAF, resulting in a prolonged exposure of sensitive tissues and organs to BAF. Consequently, when BAF and Adriamycin are used in combination, appropriate dose and schedule changes must be made to avoid any potentially serious side effects.
Similar content being viewed by others
References
Ahmann, D. L., Eagan, R. T., Bisel, H. F., et al.: Evaluation of combination therapy with Adriamycin (NSC 123127) and Methotrexate (NSC 740) in patients with disseminated breast cancer. Cancer Chemother. Rep. 6, 335 (1975)
Baker, B. R.: Active-site directed irreversible inhibitors of dehydrofolate reductase. Ann. N.Y. Acad. Sci. 214, (1971)
Benjamin, R. S.: Clinical pharmacology of Adriamycin (NSC 123127). Cancer Chemother. Rep. 6, 183 (1975)
Benjamin, R. S., Riggs, C. E., Jr., Bachur, N. R.: The pharmacokinetics and metabolism of Adriamycin in man. Clin. Pharmacol. Ther. 14, 592 (1973)
Benjamin, R. S., Loo, T. L., Friedman, J., Ho, D. H., Rodriguez, V., Gottlieb, J. A., Freireich, E. J.: Liver disease and clinical pharmacology of Baker's Antifolate (BAF, NSC 139105). Pharmacologist 17, 265 (1975)
Eagan, R. T., Ahmann, D. L., Edmonson, J. R., et al.: Controlled evaluation of the combination of Adriamycin (NSC 123127), Vincristine (NSC 67574) and Methotrexate (NSC 740) in patients with disseminated breast cancer. Cancer Chemother. Rep. 6, 339 (1975)
Goldin, A., Johnson, R. K.: Experimental tumor activity of Adriamycin (NSC 123127). Cancer Chemother. Rep. 6, 137 (1975)
Gottlieb, J. A., Burgess, M. A., Bodey, G. P., et al.: Recent developments in chemotherapy for head and neck cancer. In: Neoplasias of Head and Neck, p. 121. Chicago: Year Book Medical Publishers 1977
Huffman, D. H., Wan, S. H., Azarnoff, D. L., Hoogstraten, B.: Pharmacokinetics of Methotrexate. Clin. Pharmacol. Ther. 14 472 (1973)
Riggs, C. E., Jr., Benjamin, R. S., Serpick, A. A., Bachur, N. R.: Biliary disposition of adriamycin. Clin. Pharmacol. Ther. 22, 234 (1977)
Rodriguez, V., Gottlieb, J. A., Burgess, M. A., et al.: Phase I studies with Baker's Antifol (BAF, NSC 139105). Cancer 38, 390 (1976)
Rodriguez, V., Richman, S. P., Benjamin, R. S., Burgess, M. A., Murphy, W. K., Valdivieso, M., Banner, R. L., Gutterman, J. U., Bodey, G. P., Freireich, E. J.: Phase II study with Baker's Antifol (BAF) in solid tumors. Cancer Res. 37, 980 (1977)
Selawry, O. S.: Response of bronchogenic carcinoma to Adriamycin (NSC 123127). Cancer Chemother. Rep. 6, 349 (1975)
Author information
Authors and Affiliations
Additional information
Supported by National Cancer Institute grant USPHS Ca 14528 and contrasts N01-CM-53773 and N01-CM-57042
Rights and permissions
About this article
Cite this article
Hall, S.W., Tenczynski, T.F., Benjamin, R.S. et al. Clinical, toxicological, and pharmacological studies of combination chemotherapy of adenocarcinoma with Adriamycin and Baker's Antifolate. Cancer Chemother. Pharmacol. 1, 139–144 (1978). https://doi.org/10.1007/BF00253114
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00253114